GnuBIO
Cambridge
About GnuBIO
GnuBIO is a developer of scalable DNA sequencing technology for both the Diagnostic and Applied markets. The GnuBIO technology is an emulsion-based microfluidic technology, which provides a scalable desktop sequencing system that allows interrogation of single genes, gene panels, and whole genomes. Using a proprietary DNA sequencing system, the GnuBIO’s platform encompasses all the steps required for DNA sequencing into a single platform including target selection and enrichment, DNA amplification, DNA sequencing and analysis. GnuBIO’s cutting-edge platform provides a single user interface, and a single step process, which rapidly produces results to hours versus days.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $22.5M
- Funding stage: M&A
- Last round: Series B (Oct 2012)
- Website: gnubio.com
- Phone: 617 446 6744
Industries & Categories
Biotechnology, Genetics, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/gnubio-2813877 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.